Pulmonx Corp
$ 1.51
2.03%
24 Feb - close price
- Market Cap 61,046,000 USD
- Current Price $ 1.51
- High / Low $ 1.54 / 1.48
- Stock P/E N/A
- Book Value 1.46
- EPS -1.41
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.74 %
- 52 Week High 9.32
- 52 Week Low 1.31
About
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Analyst Target Price
$5.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-10-30 | 2023-08-02 | 2023-05-02 | 2023-02-22 |
| Reported EPS | -0.34 | -0.38 | -0.36 | -0.33 | -0.36 | -0.35 | -0.36 | -0.36 | -0.39 | -0.43 | -0.42 | -0.38 |
| Estimated EPS | -0.42 | -0.3943 | -0.3952 | -0.45 | -0.45 | -0.43 | -0.46 | -0.41 | -0.43 | -0.44 | -0.44 | -0.42 |
| Surprise | 0.08 | 0.0143 | 0.0352 | 0.12 | 0.09 | 0.08 | 0.1 | 0.05 | 0.04 | 0.01 | 0.02 | 0.04 |
| Surprise Percentage | 19.0476% | 3.6267% | 8.9069% | 26.6667% | 20% | 18.6047% | 21.7391% | 12.1951% | 9.3023% | 2.2727% | 4.5455% | 9.5238% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3948 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LUNG
2026-02-20 14:14:30
D. Boral Capital analyst Jason Kolbert has reaffirmed a Buy rating for Pulmonx (LUNG) with an unchanged price target of $14.00 USD. This decision reflects continued confidence in the medical technology company, which specializes in minimally invasive treatments for severe emphysema. Other analysts have made varying adjustments to their ratings and price targets over the past few months, with the average target price from six analysts currently at $5.75, suggesting a significant upside from its current price.
2026-02-18 14:27:30
Pulmonx Corp (PULM) has agreed to an all-cash takeover, leading to a sharp rise in its stock price. For current shareholders, the decision is whether to accept the cash offer or to hold out for a potentially higher bid, recognizing that the stock now functions as a merger arbitrage play rather than a growth stock. The acquisition offers a premium, but caps further upside, shifting the investment focus to the deal's closing probability and associated risks.
2026-02-18 13:57:38
Pulmonx Corp (NASDAQ: PULM) has agreed to an all-cash takeover, leading to a sharp rise in its stock price. For investors, the decision is now whether to accept the fixed cash offer or speculate on a higher bid, transforming the investment into a merger arbitrage situation. The deal, driven by scale, distribution synergies, and regulatory leverage, highlights a trend of innovative small-cap medtech companies exiting public markets through acquisition.
2026-02-14 03:58:08
Pulmonx, a small-cap lung-health specialist known for its Zephyr Valve, has seen its stock price significantly decline over the past year due to reimbursement challenges and execution issues. The company's recent quarterly results showed revenue growth but also highlighted ongoing operating losses and the need for continued investment. Despite underlying clinical backing for its technology, the stock's future hinges on improved reimbursement, operational execution, and capital discipline, leaving investors at a crossroads between a potential turnaround and a value trap.
2026-02-13 10:27:41
Pulmonx, a small-cap lung-health specialist known for its Zephyr Valve, is experiencing significant stock price pressure, trading near its 52-week lows. The decline is attributed to a mix of reimbursement risks, execution challenges, and a broader market rotation away from smaller, unprofitable growth companies. Despite respectable revenue growth, investors remain cautious due to ongoing operating losses and a slow path to profitability, with analysts generally holding a "Hold" or "Market Perform" stance.
2026-02-12 03:28:26
Pulmonx Corporation's shares have fallen by 29% in the last month, contributing to a 79% decline over the past year. The company's price-to-sales (P/S) ratio of 0.7x is significantly lower than the industry average, likely due to analyst forecasts predicting revenue growth of 17% annually, which is considerably less than the industry's projected 124% growth. This lower growth expectation seems to be the primary reason for investor pessimism and the depressed P/S ratio.
